Clinical Trial Update: Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa [Phase 2]

View source ↗

Summary

Phase 2 trial investigating complement inhibition for moderate to severe hidradenitis suppurativa has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Snippet

Sponsor: InflaRx GmbH | Conditions: Hidradenitis Suppurativa | Phase 2 | Status: COMPLETED